Interleukin‑37 is increased in peripheral blood mononuclear cells of coronary heart disease patients and inhibits the inflammatory reaction

Li,Huimin; Shen,Chen; Chen,Bingni; Du,Jing; Peng,Bin; Wang,Wei; Chi,Fanwu; Dong,Xiaoqiang; Huang,Zhong; Yang,Chao

doi:10.3892/mmr.2019.10805

Interleukin‑37 is increased in peripheral blood mononuclear cells of coronary heart disease patients and inhibits the inflammatory reaction

Authors:
- Huimin Li
- Chen Shen
- Bingni Chen
- Jing Du
- Bin Peng
- Wei Wang
- Fanwu Chi
- Xiaoqiang Dong
- Zhong Huang
- Chao Yang
View Affiliations

Affiliations: Department of Cardiac Surgery, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, Shenzhen, Guangdong 518020, P.R. China, Department of Pathology, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, P.R. China, Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China
Published online on: November 6, 2019 https://doi.org/10.3892/mmr.2019.10805
Pages: 151-160
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been universally acknowledged that interleukin‑37 (IL‑37) has an immunosuppressive effect on various inflammatory disorders. However, whether IL‑37 participates in the acute inflammation associated with coronary heart disease (CHD) has not yet been clarified. In the present study, the association between the serum levels of IL‑37 and the clinical indexes of CHD were analysed. In addition, the anti‑inflammatory effects of IL‑37 on peripheral blood mononuclear cells (PBMCs) were studied in CHD patients. PBMCs from 46 healthy controls (HCs) and 92 CHD patients were cultured in vitro and stimulated using the recombinant IL‑37 protein. The protein levels, as well as the mRNA expression of inflammatory cytokines (TNF‑α, IL‑1β, IL‑6, and IL‑17) were analysed by enzyme‑linked immunosorbent assay (ELISA) and real‑time polymerase chain reaction (RT‑PCR). Spearman's correlation test was performed to examine the association between the serum level of IL‑37 and the levels of pro‑inflammatory cytokines, certain clinical indexes, and disease activity during CHD. Compared to the HCs, the CHD patients, especially those with acute myocardial infarction, exhibited higher levels of IL‑37 in their PBMCs and sera. Serum levels of IL‑37 were associated with the levels of IL‑17, IL‑6, and TNF‑α, and clinical indexes such as the left ventricular ejection fraction (LVEF), amino‑N‑terminal pro‑plasma brain natriuretic peptide (NT‑proBNP) levels, and cardiac troponin T (cTnT) levels in CHD patients. Compared to the HC group, the production of inflammatory cytokines such as IL‑17, IL‑6, TNF‑α, and IL‑1β increased in the PBMCs of CHD patients and significantly decreased after the stimulation of the cells with recombinant IL‑37. The IL‑37 levels in CHD patients were high, and were correlated with the levels of CHD‑related pro‑inflammatory cytokines and disease activity. Notably, the expression of CHD‑related pro‑inflammatory cytokines in the PBMCs of CHD patients decreased following the stimulation of the cells with recombinant IL‑37, indicating that IL‑37 exerts anti‑inflammatory effects during CHD.

View Figures

View References

1	Wong ND: Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 11:276–289. 2014. View Article : Google Scholar : PubMed/NCBI
2	Libby P and Theroux P: Pathophysiology of coronary artery disease. Circulation. 111:3481–3488. 2005. View Article : Google Scholar : PubMed/NCBI
3	Ridker PM and Lüscher TF: Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 35:1782–1791. 2014. View Article : Google Scholar : PubMed/NCBI
4	Boisvert WA: The participation of inflammatory cells in atherosclerosis. Drugs Today (Barc). 37:173–179. 2001. View Article : Google Scholar : PubMed/NCBI
5	Libby P: Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 32:2045–2051. 2012. View Article : Google Scholar : PubMed/NCBI
6	Seneviratne AN and Monaco C: Role of inflammatory cells and toll-like receptors in atherosclerosis. Curr Vasc Pharmacol. 13:146–160. 2015. View Article : Google Scholar : PubMed/NCBI
7	Chistiakov DA, Orekhov AN and Bobryshev YV: Immune- inflammatory responses in atherosclerosis: Role of an adaptive immunity mainly driven by T and B cells. Immunobiology. 221:1014–1033. 2016. View Article : Google Scholar : PubMed/NCBI
8	Martinet W, Schrijvers DM and De Meyer GR: Molecular and cellular mechanisms of macrophage survival in atherosclerosis. Basic Res Cardiol. 107:2972012. View Article : Google Scholar : PubMed/NCBI
9	Bruunsgaard H, Skinhøj P, Pedersen AN, Schroll M and Pedersen BK: Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol. 121:255–260. 2000. View Article : Google Scholar : PubMed/NCBI
10	Popa C, Netea MG, van Riel PL, van der Meer JW and Stalenhoef AF: The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 48:751–762. 2007. View Article : Google Scholar : PubMed/NCBI
11	Sbarsi I, Falcone C, Boiocchi C, Campo I, Zorzetto M, De Silvestri A and Cuccia M: Inflammation and atherosclerosis: The role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol. 20:145–154. 2007. View Article : Google Scholar : PubMed/NCBI
12	Zhang H, Park Y, Wu J, Chen XP, Lee S, Yang J, Dellsperger KC and Zhang C: Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 116:219–230. 2009. View Article : Google Scholar : PubMed/NCBI
13	Iida S and Komiyama N: Balance between interleukin-1beta and interleukin-1 receptor antagonist in the development of atherosclerosis. A polymorphism in the interleukin-1 receptor antagonist. Circ J. 73:1401–1402. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lin SJ, Yen HT, Chen YH, Ku HH, Lin FY and Chen YL: Expression of interleukin-1 beta and interleukin-1 receptor antagonist in oxLDL-treated human aortic smooth muscle cells and in the neointima of cholesterol-fed endothelia-denuded rabbits. J Cell Biochem. 88:836–847. 2003. View Article : Google Scholar : PubMed/NCBI
15	Legendre F, Bogdanowicz P, Boumediene K and Pujol JP: Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular. J Rheumatol. 32:1307–1316. 2005.PubMed/NCBI
16	Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA and Maseri A: Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 99:2079–2084. 1999. View Article : Google Scholar : PubMed/NCBI
17	Kotla S, Singh NK, Heckle MR, Tigyi GJ and Rao GN: The transcription factor CREB enhances interleukin-17A production and inflammation in a mouse model of atherosclerosis. Sci Signal. 6:ra832013. View Article : Google Scholar : PubMed/NCBI
18	Usui F, Kimura H, Ohshiro T, Tatsumi K, Kawashima A, Nishiyama A, Iwakura Y, Ishibashi S and Takahashi M: Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. Biochem Biophys Res Commun. 420:72–77. 2012. View Article : Google Scholar : PubMed/NCBI
19	Zhu F, Wang Q, Guo C, Wang X, Cao X, Shi Y, Gao F, Ma C and Zhang L: IL-17 induces apoptosis of vascular endothelial cells: A potential mechanism for human acute coronary syndrome. Clin Immunol. 141:152–160. 2011. View Article : Google Scholar : PubMed/NCBI
20	Ye L, Ji L, Wen Z, Zhou Y, Hu D, Li Y, Yu T, Chen B, Zhang J, Ding L, et al: IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Its correlation with disease activity. J Transl Med. 12:692014. View Article : Google Scholar : PubMed/NCBI
21	Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C, Posselt G, et al: IL-37: A new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 22:127–147. 2011.PubMed/NCBI
22	Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P and Dinarello CA: IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 11:1014–1022. 2010. View Article : Google Scholar : PubMed/NCBI
23	Yu K, Min X, Lin Y, Huang Y, Huang S, Liu L, Peng Y, Meng K, Li D, Ji Q and Zeng Q: Increased IL-37 concentrations in patients with arterial calcification. Clin Chim Acta. 461:19–24. 2016. View Article : Google Scholar : PubMed/NCBI
24	Li J, Zhai Y, Ao L, Hui H, Fullerton DA, Dinarello CA and Meng X: Interleukin-37 suppresses the inflammatory response to protect cardiac function in old endotoxemic mice. Cytokine. 95:55–63. 2017. View Article : Google Scholar : PubMed/NCBI
25	Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 59:607–609. 1979. View Article : Google Scholar : PubMed/NCBI
26	Chen B, Huang K, Ye L, Li Y, Zhang J, Zhang J, Fan X, Liu X, Li L, Sun J, et al: Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. J Transl Med. 13:362015. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, Bamba S, Sonoda H, Shimizu T, Fujiyama Y and Andoh A: Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol. 172:410–416. 2013. View Article : Google Scholar : PubMed/NCBI
29	Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX and Jiang YF: Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One. 9:e953462014. View Article : Google Scholar : PubMed/NCBI
30	Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, Leenders F, Bufler P, Boekschoten MV, Müller M, et al: IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 5:47112014. View Article : Google Scholar : PubMed/NCBI
31	Moschen AR, Molnar C, Enrich B, Geiger S, Ebenbichler CF and Tilg H: Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med. 17:840–845. 2011. View Article : Google Scholar : PubMed/NCBI
32	Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, Blanchard J, Burns JM, Tevar AD, Edwards MJ and Lentsch AB: Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol. 27:1609–1616. 2012. View Article : Google Scholar : PubMed/NCBI
33	Chai M, Zhang HT, Zhou YJ, Ji QW, Yang Q, Liu YY, Zhao YX, Shi DM, Liu W, Yang LX, et al: Elevated IL-37 levels in the plasma of patients with severe coronary artery calcification. J Geriatr Cardiol. 14:285–291. 2017.PubMed/NCBI
34	Li Y, Wang Z, Yu T, Chen B, Zhang J, Huang K and Huang Z: Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PLoS One. 9:e1071832014. View Article : Google Scholar : PubMed/NCBI
35	Swirski FK and Nahrendorf M: Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 339:161–166. 2013. View Article : Google Scholar : PubMed/NCBI
36	Wu B, Meng K, Ji Q, Cheng M, Yu K, Zhao X, Tony H, Liu Y, Zhou Y, Chang C, et al: Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol. 176:438–451. 2014. View Article : Google Scholar : PubMed/NCBI
37	Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D and Braun J: Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis. 67:511–517. 2008. View Article : Google Scholar : PubMed/NCBI
38	Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, Novitskaya I, Khatcherian A, Bluth MJ, Lowes MA and Krueger JG: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 204:3183–3194. 2007. View Article : Google Scholar : PubMed/NCBI
39	Yang Y, Zhang ZX, Lian D, Haig A, Bhattacharjee RN and Jevnikar AM: IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and renal ischemia-reperfusion injury. Kidney Int. 87:396–408. 2015. View Article : Google Scholar : PubMed/NCBI
40	McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB, Nold MF, Nold-Petry C, Bufler P, Dinarello CA and Rivera-Nieves J: Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA. 108:16711–16716. 2011. View Article : Google Scholar : PubMed/NCBI
41	Katta S, Karnewar S, Panuganti D, Jerald MK, Sastry BKS and Kotamraju S: Mitochondria-targeted esculetin inhibits PAI-1 levels by modulating STAT3 activation and miR-19b via SIRT3: Role in acute coronary artery syndrome. J Cell Physiol. 233:214–225. 2018. View Article : Google Scholar : PubMed/NCBI
42	Zheng Y, Wang Z, Deng L, Zhang G, Yuan X, Huang L, Xu W and Shen L: Modulation of STAT3 and STAT5 activity rectifies the imbalance of Th17 and Treg cells in patients with acute coronary syndrome. Clin Immunol. 157:65–77. 2015. View Article : Google Scholar : PubMed/NCBI
43	Tete S, Tripodi D, Rosati M, Conti F, Maccauro G, Saggini A, Cianchetti E, Caraffa A, Antinolfi P, Toniato E, et al: IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. Int J Immunopathol Pharmacol. 25:31–38. 2012. View Article : Google Scholar : PubMed/NCBI
44	Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, et al: Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 127:701–721.e1-e70. 2011. View Article : Google Scholar : PubMed/NCBI